Antiplatelet effect of ticlopidine after coronary stenting

Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universitat Munchen, Munich, Germany. neumann@med1.med.tu-muenchen.de

OBJECTIVES: This study sought to investigate the contribution of ticlopidine to the inhibition of platelet activation after coronary stent placement. BACKGROUND: After coronary stenting, antiplatelet therapy with aspirin and ticlopidine improves stent patency compared with anticoagulation. However, the specific role of ticlopidine has not been elucidated. METHODS: After successful coronary stent placement, we randomized 22 patients to receive ticlopidine and aspirin (ticlopidine group) and 25 to receive aspirin alone (aspirin group). Surface expression on platelets of the activated fibrinogen receptor and of P-selectin was assessed by flow cytometry. RESULTS: In the aspirin group the percent of platelets with activated fibrinogen receptors increased between days 1 and 5 (p = 0.001), whereas there were no substantial changes in the ticlopidine group. The percent of P-selectin-positive platelets did not change significantly in the aspirin group but decreased in the ticlopidine group (p = 0.019). At day 5 after the intervention, the percent of platelets with activated fibrinogen receptors in the ticlopidine group was significantly lower (median [interquartile range]: 8.5 [3.1 to 17.8] vs. 18.1 [8.5 to 35.5], p = 0.025), and there was a trend to fewer P-selectin-positive platelets than in the aspirin group (5.8 [3.4 to 9.5] vs. 8.8 [4.0 to 15.8], p = 0.073). CONCLUSIONS: Combined antiplatelet therapy with ticlopidine plus aspirin is superior to treatment with aspirin alone in suppressing platelet activation after coronary stenting.

This article has been cited by other articles:

				D. J. Kereiakes and P. A. Gurbel Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121. [Abstract] [Full Text] [PDF]

				K. T Reaume, R. E Regal, and M. P Dorsch Indications for Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Evidence-Based Recommendations for Use Ann. Pharmacother., April 1, 2008; 42(4): 550 - 557. [Abstract] [Full Text] [PDF]

				H Dai, J Chen, Q Tao, J Zhu, F Zhang, L Zheng, and Y Qiu Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty Postgrad. Med. J., September 1, 2003; 79(935): 522 - 526. [Abstract] [Full Text]

				J. Graff, U. Klinkhardt, V. B. Schini-Kerth, S. Harder, N. Franz, S. Bassus, and C. M. Kirchmaier Close Relationship between the Platelet Activation Marker CD62 and the Granular Release of Platelet-Derived Growth Factor J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 952 - 957. [Abstract] [Full Text] [PDF]

				I. Ott, M. Andrassy, D. Zieglgansberger, S. Geith, A. Schomig, and F.-J. Neumann Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1 Blood, June 15, 2001; 97(12): 3721 - 3726. [Abstract] [Full Text] [PDF]

				E. Atalar, K. Aytemir, I. Haznedaroglu, S. Aksoyek, K. Ovunc,, S. Kirazli, and F. Ozmen Platelet and Leukocyte Deactivation After Intracoronary Stent Placement in Patients Receiving Combined Antiplatelet Therapy Clinical and Applied Thrombosis/Hemostasis, April 1, 2001; 7(2): 116 - 121. [Abstract] [PDF]

				S. R. Steinhubl, S. G. Ellis, K. Wolski, A. M. Lincoff, and E. J. Topol Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events : Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial Circulation, March 13, 2001; 103(10): 1403 - 1409. [Abstract] [Full Text] [PDF]

				C I O BROOKES and U SIGWART Taming platelets in coronary stenting: ticlopidine out, clopidogrel in? Heart, December 1, 1999; 82(6): 651 - 652. [Full Text]

				J. E. Hollander, M. R. Muttreja, M. R. Dalesandro, and F. S. Shofer Risk stratification of emergency department patients with acute coronary syndromes using P-Selectin J. Am. Coll. Cardiol., July 1, 1999; 34(1): 95 - 105. [Abstract] [Full Text] [PDF]

				M. Gawaz, F.-J. Neumann, and A. Schomig Evaluation of Platelet Membrane Glycoproteins in Coronary Artery Disease : Consequences for Diagnosis and Therapy Circulation, January 12, 1999; 99(1): e1 - e11. [Full Text] [PDF]

				R. Altman Controversies in Antithrombotic Therapy in Cardiovascular Diseases Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 11 - 24. [Abstract] [PDF]